HOPA 2018 | Recommendations for the treatment of muscle and non-muscle invasive urothelial carcinoma

Name: Recommendations for the treatment of muscle and non-muscle invasive urothelial carcinoma
Uploaded: 2018-03-21T00:00:00.000Z
Duration: 3 min 50 s

Kirollos Hanna • 21 Mar 2018

HOPA 2018

Bladder Cancer Genitourinary Cancer Atezolizumab Pembrolizumab

Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Kirollos Hanna, PharmD, BCOP, BCPS, of the University of Minnesota Medical Center, Minneapolis, MN, offers his recommendations, for colleagues in the field, on the treatment options available for muscle invasive and non-muscle invasive urothelial carcinoma. Depending on the type and severity of the disease, Dr Hanna’s recommendations include the use of chemotherapy, bladder preservation and immunotherapy.